Mengis Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Mengis Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$156K	Buy	+10,450	New	+$145K	0.02%	217

Other funds holding CRVS

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Jackson Square Capital San Francisco, California $719M AUM 144.18% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Avity Investment Management Greenwich, Connecticut $1.57B AUM 35.56% 1-Year Est. Return

Simon Quick Advisors Morristown, New Jersey $2.48B AUM 21.26% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

WhitTier Trust Company Reno, Nevada $5.35B AUM 29.91% 1-Year Est. Return

Mengis Capital Management's CRVS Position: Q2 2026 in Review

Mengis Capital Management opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 10,450 shares worth $156K. The stake represents 0.02% of the portfolio and ranks #217 among its holdings.

20 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

Mengis Capital Management held 10,450 shares of Corvus Pharmaceuticals worth $156K as of Q2 2026.
Corvus Pharmaceuticals was a new Mengis Capital Management position in Q2 2026.
Corvus Pharmaceuticals made up 0.02% of Mengis Capital Management's portfolio in Q2 2026, its #217 holding.
20 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Mengis Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.